Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03521518 · ClinicalTrials.gov registry record
CPT-3 in Normal Pressure Hydrocephalus
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- 8
- Enrollment target
NCT03521518: Clinical Trial study, sponsored by Vanderbilt University Medical Center.
NCT03521518 is a clinical trial that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03521518 was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
The study will collect prospective cohort data of individuals that are undergoing routine clinical care for suspected idiopathic Normal Pressure Hydrocephalus (NPH). The administration of the Conner's Continual Performance Test - version 3 (CPT-3), an automated 14-minute computerized measure of reaction-time and sustained attention, will be added to the current neurocognitive screen being used (i.e., the Montreal Cognitive Assessment, MoCA) along with gait assessment. Patients will undergo pre-tap testing on the morning of their large volume Lumbar Puncture (CSF-TT). These patients will receive post-tap CPT-3 and MoCA testing one-to-three hours post-tap, and again at 2-3 days post-CSF-TT, during the follow-up appointment in clinic. The standard NPH quantitative assessment methods of MoCA and gait evaluation will continue to be collected. For those patients that ultimately undergo ventricular shunt placement, the CPT-3 will be administered at their post-operative follow-up appointment (\~3 months post-operation). The results of CPT-3 will not factor into consideration for shunt candidacy.
Primary Outcome
5% Improvement in T-scores of patients after large volume lumbar puncture
Interventions
- DIAGNOSTIC_TEST Conner's Continuous Performance Test-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-01-16 |
| Est. Completion | 2023-06-01 |
Why NCT03521518 stopped before completion
NCT03521518 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Conner's Continuous Performance Test-3 is the first listed.
NCT03521518 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03521518 about?
NCT03521518 is a clinical study titled "CPT-3 in Normal Pressure Hydrocephalus". The study will collect prospective cohort data of individuals that are undergoing routine clinical care for suspected idiopathic Normal Pressure Hydrocephalus (NPH). The administration of the Conner's Continual Performance Test - version 3 (CPT-3), an automated 14-minute computerized measure of reac...
What is the current status of trial NCT03521518?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2019-01-16. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT03521518?
The interventions under investigation include: Conner's Continuous Performance Test-3 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03521518?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI